

2024 fibryga[®] Copay Enrollment Form

Please print and fax completed form to: 1-800-554-6744

If you have any questions please call the Octapharma Support Center toll free at 1-800-554-4440 | Monday to Friday 8:30 AM to 5 PM ET

PATIENT INFORMATION:

Full Name _____
Last *First* *M.I.*

Address _____ Apartment/Unit # _____

City _____ State _____ Zip _____

Date of Birth _____

Phone () _____ Email _____

PATIENT INSURANCE INFORMATION:

Name of Insurance _____ Name of Insured _____

Insurance Phone () _____ Member ID # _____ Group # _____ Plan ID # _____

COORDINATION OF CARE:

Patient Site of Care: Hospital Outpatient Infusion Center Physician Office
 Other (specify): _____

Name of Facility or Specialty Pharmacy _____

Contact Name _____ Phone () _____

FIBRYGA[®] PRESCRIBER INFORMATION:

Treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia:

IV administration: _____ mg/kg

Physician Name (print) _____
Last *First*

Address _____ Unit # _____

City _____ State _____ Zip _____

Phone () _____ Fax () _____ Email _____

PHYSICIAN SIGNATURE:

Signature _____ Date _____

By signing this form I verify that the patient and prescriber information is complete and accurate to the best of my knowledge and that I have prescribed fibryga[®] based on my professional judgment and medical necessity for the treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. I attest that I have obtained the patient's (or authorized representative's) affirmative authorization to release the above information as may be necessary to Octapharma.

2024 fibryga® Copay Enrollment Form

Page 2 of 2 Pages

TO BE ELIGIBLE:

- The patient must be receiving treatment with fibryga®, or have a prescription to begin treatment
 - The patient must have commercial insurance
 - Those with Medicare, Medicaid, Medigap, VA, DOD, Tricare or other federal or state government health insurance are not eligible
 - **Patient must use fibryga® for the FDA-approved indication of treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia, with a diagnosis code of D68.2**
- Note: Diagnosis codes are provided for reference only. Selection and documentation of an appropriate diagnosis code are the responsibility of the patient's health care provider.*
- Copay assistance may only be applied to co-payments, deductibles and co-insurance that may be associated with the cost of fibryga® up to a maximum amount of \$2,500 in copay assistance per enrollment. Enrollment can be renewed at Octapharma's discretion up to 3 times within a calendar year
 - The Copay Assistance Program does not cover costs associated with administration of therapy, such as office visits, infusion costs, or other professional services

Indications and Usage

Fibryga® is a human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Fibryga® is not indicated for dysfibrinogenemia.

Contraindications

Fibryga® is contraindicated in individuals who have manifested severe immediate hypersensitivity reactions, including anaphylaxis, to fibryga® or its components.

Warnings and Precautions

Monitor patients for early signs of hypersensitivity or allergic reactions. If necessary, discontinue administration and institute appropriate treatment. Thrombotic events have been reported in patients receiving fibryga®. Treatment with human fibrinogen concentrate has been associated with thrombosis at target plasma fibrinogen levels that were below 150 mg/dL. The thrombotic risks may be greater when the target fibrinogen plasma level is 150 mg/dL. Weigh the benefits of administration versus the risks of thrombosis.

Fibryga® is made from pooled human plasma. Products made from human plasma may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Adverse Events

The most serious adverse reactions that may be observed with fibryga® are thromboembolic episodes and anaphylactic type reactions. The most common adverse reactions observed in more than one subject in clinical studies with fibryga® (>5% of subjects) were nausea, vomiting, pyrexia (fever) and thrombocytosis.

Please see accompanying full Prescribing Information for fibryga®.